Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Survival, Costs with First-Line Pazopanib Studied

Adv Ther; 2017 Nov; Vogelzang, Pal, Ghate, et al

Elderly patients with renal cell carcinoma (RCC) treated with first-line pazopanib survived longer than those who received sunitinib, according to an analysis involving >1,000 individuals. Pazopanib treatment also resulted in lower costs and utilization. Participants with RCC were ≥65 years of age and started first-line treatment with either pazopanib (n=522) or sunitinib (n=522). Investigators looked at overall survival, costs, and utilization. Among the results:

  • The group taking pazopanib survived an average of 18.2 months, vs 14.6 months in the contingent receiving sunitinib.
  • All-cause costs were ~$8,800 and ~$10,400, respectively.
  • Inpatient costs were ~$1,500 and ~$2,500, respectively.
  • Inpatient admissions and lengths of inpatient stay were lower in the pazopanib group.

Vogelzang N, Pal S, Ghate S, et al. Clinical and economic outcomes in elderly advanced renal cell carcinoma patients starting pazopanib or sunitinib treatment: A retrospective Medicare claims analysis. Adv Ther. 2017;34(11):2452-2465. doi:10.1007/s12325-017-0628-2.

This Week's Must Reads

Perioperative radiation therapy underused in elderly patients with soft tissue sarcomas, Venigalla S et al. Intl J Rad Oncology*Biology*Physics; September (102) 2018: 155-165.

Age, R0 resection, and adjuvant radiotherapy boost outcomes in myxofibrosarcoma, Boughzala-Bennadji R et al. Intl J Rad Oncology*Biology*Physics; October (102) 2018: 399-406.

Tumor size, invasion beyond subcutaneous fat predict adverse outcomes in undifferentiated pleomorphic sarcoma, Winchester D et al. J Am Acad Dermatol. Available online 19 May 2018

High recurrence rate after pancreaticoduodenectomy for primary retroperitoneal sarcoma, Tseng W et al. European Journal of Surgical Oncology 2018 (44): June; 810-815.

Nivolumab, pembrolizumab successfully used in Kaposi sarcoma, Galanina et al. Cancer Immunol Res. 2018 Sept 7. doi: 10.1158/2326-6066.CIR-18-0121.

Must Reads in Renal Cell Carcinoma

In mRCC: Sunitinib alone not inferior to nephrectomy-sunitinib, Méjean A et al. N Engl J Med. 2018 Aug 2. doi: 10.1056/NEJMoa1803675.

Proactive management eases side effects of sunitinib treatment in RCC, Staehler M et al. Ann Oncol. 2018 Aug 23. doi: 10.1093/annonc/mdy329

Red cell distribution width might predict cancer-specific survival in RCC , Życzkowski M et al. Clinical Genitourinary Cancer 2018 June (16), e677-e683.

mRCC: Patients survive longer at high-volume centers, Joshi SS et al. Euro Urol. 2018 Sep;74[3]:387-93.

High PD1 mRNA levels tied to anti-PD1 monotherapy response, Paré L et al. Ann Oncol. 2018 Aug 27. doi: 10.1093/annonc/mdy335.